DLBCL diagnosis is a multi-step process that starts with a tissue biopsy and builds outward through protein staining, genetic testing, imaging, and blood work. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, arising from white blood cells called B-cells that grow rapidly and form tumors, most often in lymph nodes. Because DLBCL has several subtypes that behave differently and respond to different treatments, diagnosis isn’t just about confirming the cancer exists. It’s about characterizing exactly which version you have.
How DLBCL Is First Noticed
The symptom that sends most people to a doctor is a painlessly swollen lymph node, typically in the neck, armpit, or groin. These lumps grow quickly, sometimes becoming noticeable over just a few weeks. About 30% of people with DLBCL also develop what doctors call “B symptoms”: fevers above 103°F that last more than two days or come and go, drenching night sweats that soak through bedsheets, and unexplained weight loss of more than 10% of body weight over six months.
DLBCL can also start outside the lymph nodes entirely, showing up in the stomach, intestines, bones, brain, or other organs. When that happens, symptoms depend on the site. A tumor in the stomach might cause pain or nausea. One pressing on a nerve might cause numbness. The speed of growth is a distinguishing feature. Unlike slow-growing (indolent) lymphomas that can simmer for years, DLBCL tends to announce itself within weeks to months.
The Biopsy: How Tissue Is Collected
A biopsy is the only way to diagnose DLBCL. Blood tests and imaging scans can raise suspicion, but they cannot confirm it. Surgical removal of an entire lymph node (excisional biopsy) is considered the gold standard because it gives pathologists the full tissue architecture to examine. Major guidelines from both the National Comprehensive Cancer Network and the European Society for Medical Oncology recommend this approach as the standard of care for diagnosing and classifying lymphomas.
That said, a core needle biopsy, where a thick needle extracts a cylinder of tissue, is a practical alternative when the affected lymph node sits deep in the body or when a patient is elderly or too frail for surgery. In one study comparing the two approaches, excisional biopsy had a slightly higher rate of fully diagnostic results (95.2% vs. 83.8%), but 92.6% of core needle biopsies provided enough information to begin treatment without needing a second procedure. In routine practice, core needle biopsy tends to be the first choice for older patients specifically because it avoids general anesthesia.
What Happens Under the Microscope
Once the tissue is collected, a pathologist examines it under the microscope and runs a panel of protein stains called immunohistochemistry (IHC). This is where the diagnosis gets specific. The pathologist is looking for large, abnormal cells that test positive for a protein called CD20 (a marker on B-cells) and negative for CD3 (a marker on T-cells, a different type of immune cell). A high growth rate is also characteristic. In typical DLBCL, more than 80% of tumor cells are actively dividing.
Beyond confirming the diagnosis, IHC staining tells the care team which subtype of DLBCL you have. This is done using a method called the Hans algorithm, recommended by the World Health Organization. The pathologist stains for three specific proteins: CD10, BCL-6, and MUM-1. Depending on which combination lights up, the tumor is classified as either germinal center B-cell (GCB) type or activated B-cell (ABC) type. The GCB subtype accounts for roughly 40% of cases, while ABC and other non-GCB types make up the remaining 60%. This distinction matters because the two subtypes arise from B-cells at different stages of development and can respond differently to treatment.
The pathologist also checks for two proteins, BCL-2 and c-MYC, that drive cell survival and growth. When a tumor overproduces both (called double-expressor lymphoma), it tends to be more aggressive. If the initial biopsy tested positive for CD20 in the past but is now negative, the pathologist will check whether the patient previously received rituximab, a drug that targets CD20-positive cells. In that case, a different marker called CD79a can confirm B-cell origin.
Genetic Testing With FISH
After IHC, many cases require a genetic test called FISH (fluorescence in situ hybridization) to look for specific chromosomal rearrangements. The most important involve three genes: MYC, BCL2, and BCL6. When both MYC and BCL2 are rearranged, the lymphoma is reclassified as high-grade B-cell lymphoma with double-hit genetics. If all three genes are rearranged, it’s called triple-hit. These cases carry a worse prognosis and typically need more intensive treatment.
FISH works by attaching fluorescent probes to specific genes on chromosomes to see if they’ve broken apart and moved to abnormal locations. The preferred method for detecting MYC rearrangements uses a “breakapart” strategy, where probes flank both sides of the gene and separate visibly when a translocation has occurred. Standard FISH catches most of these rearrangements, but research published in Blood found that some genetic events are invisible to conventional FISH. In one study, nearly one-third of GCB-DLBCL tumors showed a double-hit gene expression pattern, yet only half of those had rearrangements detectable by standard FISH. Some MYC translocations relocated the gene next to a different gene’s regulatory region, making them invisible to both MYC and BCL6 probes.
Imaging and Staging
Once the tissue diagnosis is confirmed, a PET-CT scan maps the full extent of the disease. This scan combines a CT scan’s anatomical detail with a radioactive sugar tracer that highlights metabolically active cells, making lymphoma deposits light up throughout the body. Any focal area of increased tracer uptake in lymph nodes or organs is considered evidence of lymphoma involvement.
Staging follows the Lugano classification, a modified version of the Ann Arbor system:
- Stage I: Lymphoma in one lymph node group or one organ site outside the lymph nodes
- Stage II: Two or more lymph node groups on the same side of the diaphragm (the muscle dividing the chest from the abdomen)
- Stage III: Lymph node groups on both sides of the diaphragm, or involvement of the spleen
- Stage IV: Widespread involvement of organs beyond the lymph nodes, such as the liver, lungs, or bone marrow
Stages I and II are considered limited disease, while stages III and IV are advanced. One practical benefit of PET-CT is that it can often replace a bone marrow biopsy. If the PET-CT already shows bone marrow involvement, no separate biopsy is needed. A bone marrow biopsy is only necessary for DLBCL when the PET-CT is negative and the care team needs to check for a different, slower-growing lymphoma hiding alongside the DLBCL.
Blood Work and Prognostic Scoring
Blood tests don’t diagnose DLBCL on their own, but they play a key role in determining how aggressive the disease is likely to be. The single most important blood marker is lactate dehydrogenase (LDH), an enzyme released when cells are damaged or dividing rapidly. Elevated LDH correlates with higher tumor burden and shorter survival. In one study of 212 DLBCL patients, those with LDH levels above 301 had significantly shorter overall survival and progression-free survival. Low serum albumin, a protein made by the liver, was also linked to worse outcomes. The ratio of LDH to albumin proved to be an even stronger predictor than either value alone.
These blood values feed into a scoring tool called the International Prognostic Index (IPI), which has been the standard risk assessment for aggressive lymphoma since 1993. The IPI uses five factors, each worth one point:
- Age: Over 60 years
- LDH: Above the lab’s upper limit of normal
- Stage: III or IV disease
- Performance status: Needing help with daily activities (scored 2 or higher on the ECOG scale)
- Extranodal sites: Lymphoma in two or more organs outside the lymph nodes
A score of 0 or 1 places you in the low-risk group, while 4 or 5 indicates high risk. The IPI score helps shape treatment decisions, from the intensity of chemotherapy to whether additional targeted therapies are added. It doesn’t determine your individual outcome, but it provides a statistical framework for how similar patients have responded historically.
Putting the Diagnosis Together
A complete DLBCL diagnosis is not a single test result. It’s a composite picture assembled from biopsy confirmation, protein marker staining, genetic analysis, full-body imaging, and blood work. Each layer adds information that shapes the treatment plan. The biopsy confirms it’s DLBCL. IHC staining identifies the subtype (GCB vs. ABC). FISH testing checks for high-risk genetic rearrangements. PET-CT determines the stage. Blood work and the IPI score estimate prognosis.
From the first suspicious swollen lymph node to a finalized diagnosis, the process typically takes one to three weeks, depending on how quickly biopsy tissue is processed and whether additional genetic testing is needed. FISH results sometimes take longer than standard pathology. Because DLBCL grows fast, oncology teams generally prioritize moving through these steps quickly so treatment can begin without unnecessary delay.